News
2026/08/11
Application for initiation of clinical trials of JeYou Pharmaceuticals 'CDK4 inhibitor and CDK2-PROTAC drug candidate molecule
Shanghai JeYou Pharmaceutical Technology Co., Ltd. announced that the company's preclinical CDK4 inhibitor (JYC010145) and CDK2-PROTAC (JMKX009137) candidate drug molecules have initiated a new drug clinical trial application……
Details
08
2024/01
Jeyou Pharma's Two Innovative Macromolecular Drugs Approved for Clinical Trials
Both drugs are Class 1 new drugs, targeting sepsis and IgA nephropathy, respectively……
25
2023/12
Good news on innovation keeps coming! Jeyou Pharma has received approval for six Class 1 new drug clinical trials
The treatment areas include cancer, kidney disease, and infectious diseases...
16
2023/06
Jeyou Pharma's Innovative GARP/TGF-β1 Monoclonal Antibody Receives Approval for Clinical Trials
JYB1907 for Injection is an innovative, recombinant humanized monoclonal antibody targeting GARP/TGF-β1, independently developed by Jeyou Pharmaceuticals. It demonstrates excellent drug candidate properties and clinical therapeutic potential, and is intended for the treatment of locally advanced or metastatic solid tumors. It has previously received approval from the U.S. FDA for clinical trials……
20
2023/04
Jeyou Pharma Receives Approval for Clinical Trials of Four Class 1 New Drugs
Covering the fields of nephrology and cardiovascular and cerebrovascular diseases, demonstrating its innovative R&D capabilities……
30
2022/12
World's First JMKX000197 Injection Receives Approval for Clinical Trials
JMKX000197 is a novel small-molecule immune agonist independently developed by Jeyou Pharmaceuticals. The development of MPE indications based on this target’s mechanism of action represents a global first, and preclinical animal efficacy studies have demonstrated promising results……
18
2022/08
Jeyou Pharma has granted Genentech an exclusive license for the global development and commercialization of an innovative oral AR degrader
Shanghai Jeyou Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Jeyou Pharmaceutical”) announced that it has entered into an exclusive licensing agreement with Roche and its subsidiary Genentech (hereinafter referred to as “Genentech”)……